Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

As of January 1, your Lupron will come from a new company

Over the next few months, many patients who are being treated with Lupron Depot (leuprolide acetate) for various stages of prostate cancer may discover to their surprise that the product that used to come from TAP Pharmaceuticals and then from Abbott Laboratories is now being distributed by a company called AbbVie. … READ MORE …

Abiraterone acetate may help to eliminate cancer prior to surgery in some men with high-risk, localized disease

According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical specimens in a small percentage of men diagnosed with high-risk disease. … READ MORE …

Is an LHRH antagonist a better first-line hormone therapy than an LHRH agonist?

The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered. … READ MORE …